Free Trial

Beximco Pharmaceuticals (BXP) Competitors

Beximco Pharmaceuticals logo
GBX 38.50 0.00 (0.00%)
As of 02/21/2025

BXP vs. LSE, WPY, AHT, LAND, TW, SIR, SAFE, CLIN, EVR, and BGSC

Should you be buying Beximco Pharmaceuticals stock or one of its competitors? The main competitors of Beximco Pharmaceuticals include London Stock Exchange Group plc (LSE.L) (LSE), Worldpay (WPY), Ashtead Group (AHT), Land Securities Group (LAND), Taylor Wimpey (TW), Secure Income REIT (SIR), Safestore (SAFE), Clinigen Group (CLIN), EVRAZ (EVR), and BMO Global Smaller Companies (BGSC). These companies are all part of the "trading" industry.

Beximco Pharmaceuticals vs.

London Stock Exchange Group plc (LSE.L) (LON:LSE) and Beximco Pharmaceuticals (LON:BXP) are both large-cap finance companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership, community ranking and profitability.

Beximco Pharmaceuticals has higher revenue and earnings than London Stock Exchange Group plc (LSE.L). London Stock Exchange Group plc (LSE.L) is trading at a lower price-to-earnings ratio than Beximco Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
London Stock Exchange Group plc (LSE.L)£2.41B0.00N/A£112.40N/A
Beximco Pharmaceuticals£7.08T0.00£970.84B£9.324.13

Beximco Pharmaceuticals has a net margin of 13.71% compared to London Stock Exchange Group plc (LSE.L)'s net margin of 0.00%. Beximco Pharmaceuticals' return on equity of 13.12% beat London Stock Exchange Group plc (LSE.L)'s return on equity.

Company Net Margins Return on Equity Return on Assets
London Stock Exchange Group plc (LSE.L)N/A N/A N/A
Beximco Pharmaceuticals 13.71%13.12%6.97%

1.7% of Beximco Pharmaceuticals shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

London Stock Exchange Group plc (LSE.L) pays an annual dividend of GBX 73 per share. Beximco Pharmaceuticals pays an annual dividend of GBX 3 per share and has a dividend yield of 7.8%. London Stock Exchange Group plc (LSE.L) pays out 64.9% of its earnings in the form of a dividend. Beximco Pharmaceuticals pays out 32.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Beximco Pharmaceuticals is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, Beximco Pharmaceuticals had 1 more articles in the media than London Stock Exchange Group plc (LSE.L). MarketBeat recorded 1 mentions for Beximco Pharmaceuticals and 0 mentions for London Stock Exchange Group plc (LSE.L). Beximco Pharmaceuticals' average media sentiment score of 0.75 beat London Stock Exchange Group plc (LSE.L)'s score of 0.00 indicating that Beximco Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
London Stock Exchange Group plc (LSE.L) Neutral
Beximco Pharmaceuticals Positive

London Stock Exchange Group plc (LSE.L) received 662 more outperform votes than Beximco Pharmaceuticals when rated by MarketBeat users. Likewise, 71.83% of users gave London Stock Exchange Group plc (LSE.L) an outperform vote while only 64.67% of users gave Beximco Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
London Stock Exchange Group plc (LSE.L)Outperform Votes
770
71.83%
Underperform Votes
302
28.17%
Beximco PharmaceuticalsOutperform Votes
108
64.67%
Underperform Votes
59
35.33%

Summary

Beximco Pharmaceuticals beats London Stock Exchange Group plc (LSE.L) on 9 of the 13 factors compared between the two stocks.

Get Beximco Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for BXP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BXP vs. The Competition

MetricBeximco PharmaceuticalsDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£26.24B£2.35B£5.84B£2.64B
Dividend Yield8.67%2.92%4.75%4.98%
P/E Ratio4.134.2726.70162.45
Price / Sales0.00733.09435.29314,061.87
Price / CashN/A10.2538.0128.13
Price / Book0.007.507.645.16
Net Income£970.84B£20.70B£3.19B£5.76B
7 Day Performance-2.04%-0.11%-2.12%-1.01%
1 Month Performance-1.22%0.00%-0.45%-0.85%
1 Year Performance-4.94%97.98%16.26%39.61%

Beximco Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BXP
Beximco Pharmaceuticals
N/AGBX 38.50
flat
N/A-7.3%£26.24B£7.08T4.135,500Gap Up
LSE
London Stock Exchange Group plc (LSE.L)
N/AN/AN/AN/A£30.31B£2.41B76.694,965
WPY
Worldpay
N/AN/AN/AN/A£29.39B£4.04B194.44190
AHT
Ashtead Group
3.1818 of 5 stars
GBX 5,196
+1.6%
GBX 6,550
+26.1%
-9.1%£28.37B£13.67B18.49120Dividend Cut
LAND
Land Securities Group
2.7511 of 5 stars
GBX 589
+0.3%
GBX 675.33
+14.7%
-11.7%£4.36B£823.49M-13.66598News Coverage
TW
Taylor Wimpey
3.5528 of 5 stars
GBX 116.80
-1.0%
GBX 166.67
+42.7%
-22.1%£4.20B£3.45B17.041,090News Coverage
High Trading Volume
SIR
Secure Income REIT
N/AN/AN/AN/A£1.49B£122.40M743.55N/A
SAFE
Safestore
N/AGBX 589.50
+1.2%
N/A-25.5%£1.28B£222.85M4.86120
CLIN
Clinigen Group
N/AN/AN/AN/A£1.23B£565.60M64.691,000
EVR
EVRAZ
0.3939 of 5 stars
N/AN/AN/A£1.18B£15.40B42.1971,591
BGSC
BMO Global Smaller Companies
N/AN/AN/AN/A£769.56M£303.85M2.77N/A

Related Companies and Tools


This page (LON:BXP) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners